Recordati Industria Chimica e Farmaceutica S.p.A. (FRA:RER1)
Germany · Delayed Price · Currency is EUR 46.62
+0.44 (0.95%)
At close: Jan 30, 2026
FRA:RER1 Revenue
Recordati Industria Chimica e Farmaceutica had revenue of 632.32M EUR in the quarter ending September 30, 2025, with 13.44% growth. This brings the company's revenue in the last twelve months to 2.55B, up 12.58% year-over-year. In the year 2024, Recordati Industria Chimica e Farmaceutica had annual revenue of 2.34B with 12.45% growth.
Revenue (ttm)
2.55B
Revenue Growth
+12.58%
P/S Ratio
3.71
Revenue / Employee
562.82K
Employees
4,583
Market Cap
9.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.34B | 259.23M | 12.45% |
| Dec 31, 2023 | 2.08B | 229.02M | 12.36% |
| Dec 31, 2022 | 1.85B | 273.23M | 17.29% |
| Dec 31, 2021 | 1.58B | 131.21M | 9.06% |
| Dec 31, 2020 | 1.45B | -32.98M | -2.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mainova AG | 3.89B |
| Gelsenwasser AG | 3.36B |
| Paul Hartmann AG | 2.44B |
| Lechwerke AG | 1.06B |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
Recordati Industria Chimica e Farmaceutica News
- 17 days ago - Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Presents at 44th Annual J.P. - Seeking Alpha
- 18 days ago - Recordati Launches Isturisa In Canada For Cushing's Disease - Nasdaq
- 2 months ago - Recordati SpA (RICFY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - GuruFocus
- 2 months ago - Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Amarin outlines accelerated path to positive free cash flow in 2026 supported by Recordati partnership and $70M OpEx savings - Seeking Alpha
- 6 months ago - Italy's Recordati CEO sees rare disease drugs exempt from U.S. tariffs - Reuters
- 6 months ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 9 months ago - RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2% - GlobeNewsWire